PODD:NGS-Insulet Corporation (USD)

EQUITY | Medical Devices | Nasdaq Global Select

Last Closing

USD 180.56

Change

+8.29 (+4.81)%

Market Cap

USD 2.13B

Volume

0.99M

Analyst Target

USD 241.41
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Insulet Corp is a medical device company that develops, manufactures and sells OmniPod Insulin Management System, an insulin infusion system for people with insulin-dependent diabetes.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-15 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-0.44 (-0.61%)

USD 29.04B
BRKR Bruker Corporation

+0.46 (+0.79%)

USD 9.04B
MASI Masimo Corporation

+1.84 (+1.30%)

USD 7.53B
TMDX TransMedics Group Inc

-6.58 (-7.44%)

USD 4.17B
AXNX Axonics Modulation Technologie..

+0.05 (+0.07%)

USD 3.59B
PRCT Procept Biorobotics Corp

-3.66 (-3.79%)

USD 3.50B
LIVN LivaNova PLC

-1.63 (-3.08%)

USD 2.90B
QDEL Quidel Corporation

+0.62 (+1.62%)

USD 2.67B
NARI Inari Medical Inc

-2.08 (-4.23%)

USD 2.57B
IRTC iRhythm Technologies Inc

-1.23 (-1.60%)

USD 2.36B

ETFs Containing PODD

EDOC:AU BetaShares Digital Health.. 8.61 % 0.00 %

+0.18 (+-0.53%)

N/A
EDOG:LSE Global X Telemedicine & D.. 5.40 % 0.00 %

+0.05 (+-0.53%)

USD 0.38M
EDOC:LSE Global X Telemedicine & D.. 5.28 % 0.00 %

+0.05 (+-0.53%)

USD 3.69M
DDOC:XETRA Global X Telemedicine & D.. 4.93 % 0.00 %

+0.03 (+-0.53%)

USD 5.39M
DDOC:F Global X Telemedicine & D.. 4.93 % 0.00 %

-0.03 (-0.53%)

USD 4.62M
EDOC:SW Global X Telemedicine & D.. 4.91 % 0.00 %

+0.09 (+-0.53%)

N/A
EKG First Trust Nasdaq Lux Di.. 4.66 % 0.00 %

+0.04 (+-0.53%)

USD 2.49M
CIB0:XETRA VanEck Bionic Engineering.. 4.44 % 0.00 %

-0.18 (-0.53%)

USD 5.03M
FDOC:LSE Fidelity Digital Health U.. 4.35 % 0.00 %

N/A

USD 3.02M
CURG:LSE VanEck Genomics and Healt.. 4.34 % 0.00 %

+0.06 (+-0.53%)

USD 5.12M
GDOC Goldman Sachs ETF Trust 4.14 % 0.00 %

-0.28 (-0.53%)

USD 0.02B
FDHT 4.07 % 0.00 %

N/A

N/A
FDHT:XETRA Fidelity Digital Health U.. 4.04 % 0.00 %

-0.03 (-0.53%)

N/A
CYBG:LSE VanEck Bionic Engineering.. 3.90 % 0.00 %

-0.02 (-0.53%)

N/A
CURE:XETRA VanEck Genomics and Healt.. 3.57 % 0.00 %

-0.06 (-0.53%)

N/A
FXH First Trust Health Care A.. 2.35 % 0.63 %

+0.33 (+-0.53%)

USD 1.18B
SAGP The Advisorsa Inner Circl.. 2.04 % 0.00 %

-0.16 (-0.53%)

USD 0.04B
2B78:XETRA iShares Healthcare Innova.. 1.81 % 0.00 %

+0.01 (+-0.53%)

USD 1.14B
2B78:F iShares Healthcare Innova.. 1.81 % 0.00 %

N/A

N/A
HEAL:SW iShares Healthcare Innova.. 1.72 % 0.00 %

+0.01 (+-0.53%)

N/A
EUSA iShares MSCI USA Equal We.. 0.21 % 0.15 %

-0.13 (-0.53%)

USD 0.92B
SLIM 0.00 % 0.50 %

N/A

N/A
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

+3.00 (+-0.53%)

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

+0.08 (+-0.53%)

N/A
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

+0.01 (+-0.53%)

USD 0.04B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.78% 51% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.78% 51% F 27% F
Trailing 12 Months  
Capital Gain -42.34% 41% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.34% 41% F 21% F
Trailing 5 Years  
Capital Gain 73.78% 84% B 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 73.78% 84% B 78% C+
Average Annual (5 Year Horizon)  
Capital Gain 11.93% 63% D 71% C-
Dividend Return 11.93% 63% D 70% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 34.63% 83% B 53% F
Risk Adjusted Return 34.47% 84% B 69% C-
Market Capitalization 2.13B 97% N/A 93% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 56.53 32% 18%
Price/Book Ratio 16.75 15% 7%
Price / Cash Flow Ratio 80.03 2% 3%
Price/Free Cash Flow Ratio 40.13 7% 6%
Management Effectiveness  
Return on Equity 34.13% 100% 95%
Return on Invested Capital 11.34% 85% 80%
Return on Assets 6.09% 92% 89%
Debt to Equity Ratio 186.49% 15% 12%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.